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Abstract
Background There are limited data available concerning
endofistular therapies for fistula-in-ano, with our group
reporting the first preliminary outcomes of the use of the
radial fibre Fistula laser Closing (FiLaC TM) device.
Methods The aim of this study was to assess a cohort of
anal fistulae managed with laser ablation plus definitive
flap closure of the internal fistula opening over a long-term
follow-up. Factors governing primary healing success and
secondary healing success (i.e. success after one or two
operations) were determined.
Results The study analysed 117 patients over a median
follow-up period of 25.4 months (range 6–60 months) with
13 patients (11.1%) having Crohn’s-related fistulae. No
incontinence to solid and liquid stool was reported. Minor
incontinence to mucus and gas was observed in two cases
(1.7%), and a late abscess treated in one case (0.8%). The
primary healing rate was 75/117 (64.1%) overall, and
63.5% for cryptoglandular fistulae versus 69.2% for
Crohn’s fistulae, respectively. Of the 42 patients who failed
FiLaCTM 31 underwent a second operation (‘‘Re-
FiLaCTM’’, fistulectomy with sphincter reconstruction or
fistulotomy). The secondary healing rate, defined as heal-
ing of the fistula at the end of the study period, was
103/117 (88.0%) overall and 85.5% for cryptoglandular
fistulae versus 92.3% for Crohn’s fistulae. A significantly
higher primary success rate was observed for intersphinc-
teric-type fistulae with primary and secondary outcome
unaffected by age, gender, presence of Crohn’s disease,
number of prior surgeries and the type of flap designed to
close the internal fistula opening.
Conclusions There is a moderate primary success rate
using first-up FiLaCTM treatment. If FiLaCTM fails, sec-
ondary success with repeat FiLaCTM or other approaches
was high. The minimally invasive FiLaCTM approach may
therefore represent a sensible first-line treatment option for
anal fistula repair.
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Introduction
Recently, alternative therapies have been employed in the
management of cryptogenic anal fistula in an attempt to
render the surgery more minimally invasive and to reduce
the likelihood of post-operative faecal incontinence [1].
These treatments have included ligation of the inter-
sphincteric fistula tract (the LIFT procedure) either with or
without the deployment of a biosynthetic mesh [2], or fis-
tula clip closure techniques [3] and a range of endofistular
therapies including video-assisted anal fistula treatment
(VAAFT) [4], anal fistula plugs [5] and a variety of
injected biomaterials [6]. The ‘‘Fistula Laser Closing’’
(FiLaCTM) device (Biolitec, Germany) is another endofis-
tular management technique, and its preliminary results in
a small cohort were previously reported by our group [7]
and two other surgical units [8–10].
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The FiLaCTM technique as previously described [7] uses
a radial-emitting disposable laser fibre for endofistular
therapy and may be supplemented in selected cases with a
mucosal advancement anoplasty for control of the internal
fistula opening. With other techniques such as bioprosthetic
plugs and glues, the principal reasons for fistula recurrence
include missed and untreated internal openings, insufficient
drainage of the intersphincteric space, missed sidetracks
and/or retained remnants of fistula epithelium and granu-
lation tissue [11–13]. The FiLaCTM approach is designed to
destroy both the crypt gland and the additional epithelial
layer of the fistula track simultaneously by a photothermal
effect with coincident obliteration of both the internal and
external fistula orifices. This study presents an extension of
our original pilot work analysing the first 5 years of our
experience employing an unselected approach with the
FiLaCTM device in the management of patients with high
anal fistulae.
Materials and methods
The study was approved by the local hospital ethics com-
mittee, and all patients undergoing the FiLaCTM procedure
provided informed consent. The study analysed 117
patients treated for anal fistulae in a single tertiary referral
centre by one experienced colorectal surgeon (AW)
between October 2009 and July 2014. Fistulae were clas-
sified in accordance with the Parks’ classification system
[14], and all patients were preoperatively assessed by
clinical examination and proctosigmoidoscopy and classi-
fied using three-dimensional (3D) endoanal ultrasonogra-
phy (B-K Medical, Copenhagen, Denmark) performed by a
sonographer experienced in endoluminal anal ultrasound
(AW). Very superficial fistulae where fistulotomy could be
performed without compromising sphincter function and
malignant fistulae were excluded from analysis.
Basic patient demographic data (age, sex) along with
fistula type and information (where available) concerning
prior surgical treatments were collected. A simple ques-
tionnaire was used to assess post-operative continence
status. In 110 cases, there was prior drainage of an abscess
with removal of side tracks, identification of the internal
fistula opening and selective insertion of a seton (where
appropriate) into the main fistula track using a 2-mm latex
vessel loop (Ethiloop, Ethicon Products, Germany) at the
initial operation. Seven patients had a chronic fistula and
underwent immediate fistula repair by laser. Before a
definitive fistula repair with the FiLaC TM device, all
patients underwent mechanical bowel preparation with 3 L
Oralav (Macrogol, B. Braun Melsungen AG, Germany)
and received 2 g intravenous cefuroxime plus 500 mg
metronidazole intravenously and two further doses of
metronidazole over the first post-operative 24 h.
At the commencement of each treatment, the external
and internal orifices of the fistula track were excised, fol-
lowed by the preparation of a flap. Depending upon the
local tissue situation in the area of the internal opening
either an advancement, mucosal or anodermal flap was
made. The fistula track was cleaned mechanically using a
curette and irrigated with saline. The internal opening
within the internal sphincter muscle was closed by means
of a 2/0 Vicryl suture, and the laser probe was inserted
from the perineal opening. For suprasphincteric type 3
fistulas, the probe was inserted primarily from the internal
orifice to reach the ‘‘turning point’’ of the fistula track in
order to close the transmuscular fistula component. Then,
the internal opening was closed using 2/0 Vicryl, and the
subcutaneous part of the fistula track was treated with the
laser from the outer opening as described above.
The laser probe was inserted through the perineal fis-
tula opening using either a ‘‘Ceralas’’ (or more recently,
a ‘‘Leonardo DUAL 45’’) diode laser (Biolitec AG,
Germany). This type of laser delivers energy at a wave-
length of 1470 nm (Fig. 1) providing an optimal absorp-
tion curve in water which is considered to result in a
more efficient local tissue shrinkage and protein denatu-
ration. When there is no longer any water in the tissue
and the temperature exceeds 100 C, a white smoke
vaporization effect is observed. The use of this wave-
length by the radial-tip laser fibre permits destruction of
the granulation and epithelial tissue causing a 2- to 3-mm
zone of controlled tissue damage with less power (13 W)
and a diminished likelihood of perifistular collateral
Fig. 1 Leonardo DUAL 45 diode laser from Biolitec AG,
Germany. Wavelength 980–1470 nm. Maximum energy 15 Watts
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thermal damage [7]. In those suprasphincteric (Parks’
Type 3) fistulae, the laser probe is introduced via the
internal fistula opening reaching the ‘‘turning point’’ of
the fistula track so as to obliterate the intersphincteric
component. For obliteration, the fistula track is treated
with a continuous slow retraction of the laser fibre
withdrawn at a rate of approximately 1 cm per 3 s
(Fig. 2). Treatment progress is assessed by probing the
track either with the laser fibre or with a metal fistula
probe. Clearly, over-burning or protein denaturation of the
treated and surrounding tissue should be avoided. The
internal opening was closed using a 2/0 Vicryl suture
creating either a mucosal advancement or an anodermal
flap depending upon the local tissue circumstances.
Post-operatively, there were no dietary restrictions,
and all patients were placed on stool softeners (Muco-
falk) for a 2-week period. Patients were discharged on
either the 2nd or the 3rd post-operative day. Follow-up
was conducted on the 4th and 10th post-operative days
and at 6 weeks, 3 months, 6 months and 1 year there-
after. Further follow-up was carried out at yearly inter-
vals, and patients were instructed to return to the clinic
in the interim if symptoms recurred. A fistula was con-
sidered to have permanently healed if at 1 year all
symptoms had completely disappeared, there was no
evidence of recurrence (or persistence) on clinical,
proctoscopic and endosonographic examination and there
were no additional interventions required. Healing after
the first FiLaC TM laser treatment was defined as primary
success, and healing following a repeat operative therapy
after initial laser treatment failure was defined as sec-
ondary success (Table 1).
In the event of treatment failure, there was selective
management at the discretion of the surgeon which inclu-
ded repeat laser treatment, fistula excision with partial
sphincter reconstruction (if\30% of the sphincter complex
was involved) or complete fistula excision with major
sphincter reconstruction (if[30% of the sphincter complex
was involved), and Fig. 3 shows a lay-open fistulotomy and
plug repair (Table 2).
Statistical analysis
Statistical analysis was performed with SAS 9.4 software
(SAS Institute Inc., Cary NC, USA) using the FREQ,
UNIVARIATE and NPAR1WAY program procedures, as
appropriate. Differences in treatment success between
patient subgroups were quantified as healing rate ratios
(HRRs) with 95% confidence intervals (95% CI) and
assessed for statistical significance using Fisher’s exact
test. The largest subgroup was consistently chosen as the
reference group. Age distributions were characterized by
their median and interquartile range. A Kruskal–Wallis
rank test was used to assess age differences between patient
subgroups for statistical significance. Two-sided p val-
ues\ 0.05 were considered significant.
Fig. 2 FiLaCTM treatment of a transsphincteric anal fistula. a De-
monstrating the track with a fistula probe. b The laser fibre is inserted
into the fistula track. The red light indicates the tip of the fibre inside
the rectum. c Internal orifice following laser treatment. The necrotic





Of the 117 patients, 35 were female and 82 were male
(overall median age 46 years; range 17–82 years). The
median period of follow-up was 25.4 months (range
6–60 months). In the cohort, 104 fistulae (88.9%) were
cryptoglandular in origin and 13 (11.1%) were Crohn’s
related. One hundred and thirteen patients (96.6%) had
previously undergone surgery including abscess drainage
and prior fistula operations. The mean number of operations
before FiLaC TM treatment was 2.4 (±1.7) with a range of
1–9 previous operations. Primary operations had been per-
formed elsewhere in 62 cases (53.0%). Seven patients (6.0%)
underwent immediate definitive laser treatment without
prior abscess drainage and 11 (9.4%) underwent FiLaC TM
treatment without deployment of a seton following abscess
drainage performed elsewhere. A seton was placed in 99
patients (84.6%) with a mean period between seton insertion
and definitive fistula treatment of 16.1 (±29.2) weeks.
Sixteen patients (13.7%) had a persistent fistula following
previous outside fistula repair before laser treatment was
performed. Out of this group, 6 (46.0%) had two previous
attempts to repair the fistula (Table 3).
The overall results of the studywith primary and secondary
success rate in relation to the different variables are listed in
Table 1. The primary success rate of the FiLaCTM procedure
was 64.1% (75/117) with no difference in this outcome noted
between cryptoglandular (63.5%; 66/104) and Crohn’s
(69.2%; 9/13) cases (HRR 1.09, 95% CI 0.74,1.61). The
secondary success rate was 88.0% (103/117) with no differ-
ence noted in this outcome measure between cryptoglandular
(85.5%; 89/104) and Crohn’s-related cases (92.3%; 12/13;
HRR 1.05, 95%CI: 0.89, 1.29). Sex also lacked a statistically
significant effect upon both the primary success rate (male:
62.2%; 51/82 vs. female: 68,5%; 24/35; HRR 1.10, 95 CI
0.83,1.50) and the secondary success rate (86.5%; 71/82 vs.
91.4%; 32/35; HRR 1.06, 95 CI 0.92,1.21). No significant
effect on either the primary or secondary success rate was
Table 1 Primary and secondary success rates after FiLaCTM
Patient characteristics n Primary healing Secondary healing#
Yes (%) No (%) HRR (95% CI) p$ Yes (%) No (%) HRR (95% CI) p$
n 117 75 (64.1) 42 (35.9) 103 (88.0) 14 (12.0)
Age& 47 (19) 45.5 (19) 0.278 46 (17) 42.5 (20) 0.980
Sex
Male 82 51 (62.2) 31 (37.8) *** 71 (86.6) 11 (13.4) ***
Female 35 24 (68.5) 11 (31.5) 1.10 (0.83,1.50) 0.537 32 (91.4) 3 (8.6) 1.06 (0.92,1.21) 0.550
Aetiology
Cryptoglandular 104 66 (63.5) 38 (36.5) *** 91 (87.5) 13 (12.5) ***
Crohn 13 9 (69.2) 4 (30.8) 1.09 (0.74,1.61) 0.768 12 (92.3) 1 (7.7) 1.05 (0.89,1.25) 1.000
Park classification
I 8 8 (100.0) 0 (0.0) 1.63 (1.39,1.93) 0.048 8 (100.0) 0 (0.0) 1.12 (1.05,1.21) 1.000
II 90 55 (61.1) 35 (38.9) *** 80 (88.9) 10 (11.1) ***
III 13 8 (61.5) 5 (38.5) 1.01 (0.64,1.60) 1.000 10 (76.9) 3 (23.1) 0.87 (0.64,1.18) 0.211
IV 6 4 (66.7) 2 (33.3) 1.09 (0.61,1.97) 1.000 5 (83.3) 1 (16.7) 0.94 (0.65,1.35) 0.528
Closure technique
MSAF 51 34 (66.7) 17 (33.3) 1.02 (0.77,1.35) 1.000 46 (90.2) 5 (9.8) 1.04 (0.91,1.20) 0.760
Anodermal flap 52 34 (65.4) 18 (34.6) *** 45 (86.5) 7 (13.5) ***
Mucosal flap 2 1 (50.0) 1 (50.0) 0.76 (0.19,3.10) 1.000 1 (50.0) 1 (50.0) 0.58 (0.14,2.32) 0.277
Suture closure 12 6 (50.0) 6 (50.0) 0.76 (0.42,1.39) 0.341 11 (91.7) 1 (8.3) 1.06 (0.87,1.30) 1.000
Prior fistula repair§
Yes 16 9 (56.3) 7 (43.7) 0.86 (0.55,1.36) 0.577 13 (81.3) 3 (18.7) 0.91 (0.71,1.16) 0.405
No 101 66 (65.3) 35 (34.7) *** 90 (89.1) 11 (10.9) ***
HRR healing rate ratio, MSAF mucosal–submucosal advancement flap
$ p value from Fisher’s exact test except for age, where the p value is from a Kruskal–Wallis test
*** Indicates reference group; 9% CI 95% confidence interval
# Defined as healing at the end of study
§ Defined as any surgery except I/D of abscess and seton replacement
& Median (interquartile range)
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observed for patient age (Kruskal–Wallis test p = 0.278 and
p = 0.980, respectively), the endurance of previous fistula
repair (Fisher’s exact test p = 0.577 and p = 0.405, respec-
tively) or the closure technique of the internal orifice (Fisher’s
exact test, all p[ 0.05). Finally, secondary treatment success
rates were not found to be depended on either the number of
previous operations or the time interval between the prior and
the definitive procedure (data are not shown).
The only statistically significant determinant of treat-
ment success was found to be disease severity. A 1.63-fold
increase in primary success rate was observed for fistulae
Parks—St. Marks type 1 as compared to type 2 patients,
used as the reference group (95% CI 1.39, 1.93). In fact,
first treatment was successful in all eight type 1 patients,
compared to only 55 of 90 type 2 patients (61%, Fischer’s
exact p = 0.048). Type 3 and type 4 cases showed similar
treatment success rates as type 2 patients, and comparable
albeit weaker effects of disease severity were consistently
observed for the secondary success rates (Table 1).
No major forms of incontinence (solid, liquid stool or
gas) were reported, with minor soiling noted in seven
patients (5.9%) (three patients after primary FiLaCTM
procedure and four patients after a repeated second fistula
surgery). Five of whom had an additional advancement flap
to cover the internal opening. Another five of the seven
patients responded to rubber band ligation for coincident
mucosal prolapse/ectropion. In the total cohort, there was
one patient (0.8%) who developed a late abscess and one
patient (0.8%) who died of an unrelated cancer during the
follow-up period. In those patients where there was initial
failure of the FiLaCTM procedure, distalization of the pri-
mary track (conversion from a high to a low fistula) was
observed in half (21/42) of the cases. At the time of follow-
up, 11 patients (9.4%) still have their fistula and have
declined a second operative attempt at cure.
Discussion
Minimally invasive fistula management, which balances
clinical effectiveness with an absence of post-operative
functional disturbance has been the ‘‘holy grail’’ of anal
fistula treatment since Tasci first presented a novel ‘‘fis-
tulectome’’ device in 2003, designed to mechanically core
out the primary fistula track [15]. This approach has been
extended by Rojanasakul and others with the ligation of
the intersphincteric fistula tract (LIFT) procedure [16, 17].
Further extension of this idea towards totally endofistular
therapy was advanced by our group’s preliminary report
of the FiLaCTM procedure [7] with success in 9/11 cases
over a median follow-up of 7.4 months and by Meinero
and Mori [3, 18], with their ‘‘video-assisted anal fistula
treatment’’ (VAAFTTM) technique. These latter two
Table 2 Secondary success
rates after reoperation for an
initial failed FiLaCTM procedure
Reoperation Secondary healing Secondary success rate (%)
Repeat FiLaCTM procedure 3/5 60
Excision and partial sphincter reconstruction 16/16 100
Excision and major sphincter reconstruction 7/7 100
Gore-Plug 0/1 0
Lay-open fistulotomy 2/2 100
Table 3 Previous fistula repair before FiLaCTM treatment
First operation Second operation
Flap repair 12 2
Plug 4 1
LIFT 0 1
Fig. 3 Lay open after failed FiLaCTM treatment. A formerly high
transsphincteric fistula became ‘‘distalized’’ (more superficial) per-
mitting delayed fistulectomy without disruption of continence
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methods were first reported in 2011 in Techniques in
Coloproctology.
This study reports the long-term outcomes of a cohort of
117 patients presenting with anal fistulae where there was a
unit policy towards formal flap closure of the internal fis-
tula opening and as such represents (as far as we are aware)
the largest series of FiLaCTM—treated anal fistula cases
currently available. The primary success rate over a median
follow-up of 25.4 months was moderate, and the secondary
success rate was high regardless of whether the fistula is
cryptoglandular or Crohn’s related in origin. Primary and
secondary healing is more likely if the initial fistula is less
complicated, and there is no specific advantage of a par-
ticular flap technique (when used to close the internal fis-
tula opening definitively). Patient demographics, the
number of prior operations or the timing of definitive
surgery have no effect on successful outcome. In our study,
as in other available reports, no major faecal incontinence
was reported [8, 10].
It is recognized that although many sphincter-preserving
techniques have provided encouraging preliminary results,
over time they have failed to live up to their initial promise
[19]. As an outcome measure, a high secondary healing
rate is an essential gauge of success of any novel fistula
therapy particularly when patients referred to a tertiary
institution have had multiple prior failed procedures and
where continence may already be partially disturbed. The
lack of formal prospective continence assessment is lack-
ing limitation of our study, but it will be a specific focus in
future work. Moreover, although the cohort size is com-
paratively small, it is particularly encouraging that Crohn’s
disease does not seem to have any influence on either
primary or secondary outcomes following FiLaCTM treat-
ment. The distalization of the primary fistula track in half
of the cases where an initial FiLaCTM procedure had failed
also permits a much easier repeat fistulectomy with or
without the need for a subsequent sphincter repair. In our
operative strategy to avoid any kind of faecal incontinence,
only two cases of a very low persistent fistula were suit-
able for a lay-open procedure. In cases with muscular
involvement of up to 30% on clinical examination, we did
a fistulectomy with ‘‘partial’’ and, in patients with up to
50% involvement, a fistulectomy with a ‘‘major’’ sphincter
reconstruction. If a high fistula track persisted and involved
more than 50% of the muscle, a second sphincter-saving
procedure like ‘‘re-FiLaCTM’’ or ‘‘Gore-Plug’’ was per-
formed. The precise mechanism of this shift from a high to
a low anal fistula is unclear, but it may be a specific feature
of the tissue-modulating effect of the laser.
Lasers have been used as surgical tools for anal diseases
for the past four decades [20] with the first report of a CO2
laser in 1981 [21] being used to treat three cryptogenic anal
fistulae by coring out the fistula track followed by a 2001
Saudi Arabian study reporting six anal fistula cases treated
with a KTP solid-state laser combined with fibrin glue
instillation [22]. Similar success rates using a CO2 laser
therapy in complex Crohn’s-related anal fistulae have also
been previously reported [23]. In the past, a range of bare-
tip diode lasers with variable wavelengths (810, 940 and
980 nm) were used for anal fistulae, borrowing from the
effect observed with these types of lasers in a range of
endovenous procedures [24]. In the present study, we used
a diode laser with a wavelength of 1470 nm and a circular
emitting laser fibre, which is estimated to have a 60 times
higher efficiency to shrink and seal the fistula track by
interacting with water and blood at a lower energy com-
pared to 980 nm. Earlier diode lasers with lower wave-
lengths (around 980 nm) have been reported to be
successful because of their enhanced coagulating effect [8].
The photothermal effect and the optimal shrinkage
obtained with a radial-tip fibre result in a more controlled
damage, which is confined to the fistula lumen so that the
limited radial penetration depth (2–3 mm beyond the fis-
tula track) results in minimal collateral sphincter injury.
The reduction in laser energy with the shift from a 980-nm
to a 1470-nm probe has also resulted in lower pain scores
in a study reported by Giamundo et al. treating 35 patients
with the FiLaCTM probe [8].
The use of definitive closure of the internal fistula
opening en passant with the FiLaCTM procedure remains
controversial. Although the flap technique appears to be
unassociated with primary or secondary FiLaCTM success
rates, our approach has been formally to close the internal
fistula orifice and to choose the type of flap closure on a
case-by-case basis. It is recognized that formal fistula
excision combined with sphincter reconstruction is asso-
ciated with a 20% rate of post-operative faecal inconti-
nence [25] and that in management of complex fistulas
even the traditional flap techniques alone can be associated
with incontinence rates of up to 43% [26]. The prospective
assessment of the recurrence rate is dependent upon the
ability of the laser alone to completely seal the inner part of
the fistula track. Giamundo et al. [8, 10] have treated anal
fistulae entirely with the laser probe without the need for
closure of the internal opening. In this respect, most
recurrences appear to occur relatively early following
FiLaCTM treatment and are likely the result of fistula
reopening with a linking up of the epithelial remnants of
small undetected secondary tracks before the denaturation
effect of the laser can take effect.
The role of preliminary seton deployment before
definitive FiLaCTM therapy requires further examination
possibly in a randomized, controlled trial. In our study, the
majority of patients had an indwelling seton. In the most
recent studies by Giamundo et al. [8, 10], the presence of
the seton resulted in a better success rate (although this did
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not reach statistical significance in a small group of
patients). One other study by O¨zturk et al. [9] reporting
high success rates with FiLaCTM therapy did not include
seton management as part of a first operative stage. The
laser fibre is easier to insert in those patients which already
have an indwelling seton, and in this setting the seton can
be used to railroad the laser probe across the fistula (Sel-
dinger manoeuvre) and to assist maturation of the principal
track by inducing a more homogeneous fibrotic reshaping
of the fistula lumen. Such an effect would permit a more
uniform shrinkage distribution along the fistula track when
the laser is employed in the second-stage procedure. The
use of a seton and conversion of a ‘‘one-stage’’ to a ‘‘two-
stage’’ procedure will have the benefit of preliminary
drainage of abscesses and the intersphincteric space and
should encourage small secondary tracks to close improv-
ing the likelihood of advancement flap healing if this is
used as a supplementary technique.
The FiLaCTM procedure combines the aims of fistula
management, namely clinical effectiveness and the
maintenance of continence function. Although it is
essentially a ‘‘blind’’ procedure that has the potential of
missing some small secondary tracks, it is clearly safe
and does not induce short-term post-operative sepsis. The
long-term results show moderate primary and high sec-
ondary healing rates for the majority of fistula types and
success rates unaffected by the nature and number of
prior procedures or by the presence of Crohn’s disease.
The minimally invasive FiLaCTM approach may there-
fore represent a sensible first-line treatment option for
anal fistula repair. Randomized, controlled trials are
needed to assess its performance against other minimally
invasive fistula therapies.
Compliance with ethical standards
Conflict of interest Dr. Arne Wilhelm has received travelling grants
and speaker honoraria from Biolitec AG, Germany, and THD Spa,
Italy.
Ethical approval All procedures performed in studies involving
human participants were in accordance with the ethical standards of
the institutional and/or national research committee and with the 1964
Helsinki Declaration and its later amendments or comparable ethical
standards.
Informed consent All patients undergoing the FiLaCTM procedure
provided informed consent.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Limura E, Giordano P (2015) Modern management of anal fis-
tula. World J Gastroenterol 21:12–20
2. Han JG, Wang ZJ, Zheng Y et al (2016) Ligation of Inter-
sphincteric Fistula Tract vs Ligation of the Intersphincteric Fis-
tula Tract plus a bioprosthetic anal fistula plug procedure in
patients with transsphincteric anal fistula: early results of a
multicenter prospective randomized trial. Ann Surg 264:917–922
(PMID: 26606429)
3. Dubois A, Carrier G, Pereira B et al (2015) Therapeutic man-
agement of complex anal fistulas by installing a nitinol closure
clip: study protocol of a multicentric randomised controlled trial–
FISCLOSE. BMJ Open 16:e009884
4. Meinero P, Mori L (2011) Video-assisted anal fistula treatment
(VAAFT): a novel sphincter-saving procedure for treating com-
plex anal fistulas. Tech Coloproctol 15:417–422
5. Ko¨ckerling F, Alam NN, Narang SK, Daniels IR, Smart NJ
(2015) Treatment of fistula-in-ano with fistula plug—a review
under special consideration of the technique. Front Surg 16:55
6. Scoglio D, Walker AS, Fichera A (2014) Biomaterials in the
treatment of anal fistula: hope or hype? Clin Colon Rect Surg
27:172–181
7. Wilhelm A (2011) A new technique for sphincter-preserving anal
fistula repair using a novel radial emitting laser probe. Tech
Coloproctol 15:445–449
8. Giamundo P, Geraci M, Tibaldi L, Valente M (2013) Closure of
fistula-in-ano with laser—FiLaCTM: an effective novel sphincter-
saving procedure for complex disease. Colorectal Dis 16:110–115
9. O¨ztu¨rk E, Gu¨lcu¨ B (2014) Laser ablation of fistula Tract: a
sphincter-preserving method for treating fistula-in-ano. Dis Colon
Rectum 57:360–364
10. Giamundo P, Esercizio L, Geraci M, Tibaldi L, Valente M (2015)
Fistula-tract laser closure (FiLaC TM): long-term results and new
operative strategies. Tech Coloproctol 19:449–453
11. Lunnis PJ, Sheffield JP, Talbot IC, Thomson JP, Phillips RK
(1995) Persistence of idiopathic anal fistula may be related to
epithelialisation. Br J Surg 82:32–33
12. Litza EM, van Wijk JJ, Gosselink MP, Doornebosch P, Zim-
merman DDE, Schouten WR (2010) Seton drainage prior to
transanal advancement flap repair: useful or not? Int J Colorectal
Dis 25:1499–1502
13. Sygut A, Mik M, Trzcinski R, Dziki A (2010) How the location
of the internal opening of anal fistulas affect the treatment results
of primary transsphincteric fistulas. Langenbecks Arch Surg
395:1055–1060
14. Parks AG, Gordon PH, Hardcastle JD (1976) A classification of
fistula-in-ano. Br J Surg 63:1–12
15. Tasci I (2003) The fistulectome: a new device for treatment of
complex anal fistulas by ‘‘Core-Out’’ fistulectomy. Dis Colon
Rectum 46:1566–1571
16. Rojanasakul A, Pattanaarun J, Sahakitrungruang C, Tan-
tiphlachiva K (2007) Total anal sphincter saving technique for
fistula-in-ano; the ligation of intersphincteric fistula tract. J Med
Assoc Thai 90:581–586
17. Zirak-Schmidt S, Perdawood SK (2014) Management of anal
fistula by ligation of the intersphincteric fistula tract—a system-
atic review. Dan Med J 61:A4977
18. Meinero P, Mori L, Gasloli G (2014) Video-assisted anal fistula
treatment: a new concept of treating anal fistulas. Dis Colon
Rectum 57:354–359
19. Narang SK, Keogh K, Alam NN, Pathak S, Daniels IR, Smart NJ
(2017) A systematic review of new treatments for cryptoglan-
dular fistula in ano. Surgeon 15:30–39
Tech Coloproctol
123
20. Iukhvidova ZhM, Makeeva NS, Zinov’eva OI, Sidorova TA
(1978) Use of lasers in the treatment of diseases of the anorectal
region. Sov Med 2:86–90
21. Slutzki S, Abramsohn R, Bogokowsky H (1981) Carbon dioxide
laser in the treatment of high anal fistula. Am J Surg 141:395–396
22. Salim AS, Ahmed TM (2001) KTP-Laser and fibrin glue for
treatment of fistulae in ano. Saudi Med J 22:1022–1024
23. Moy J, Bozdin J (2006) Carbon dioxide laser ablation of perianal
fistulas in patients with Crohn’s disease: experience with 27
patients. Am J Surg 191:424–427
24. Doganci S, Demirkilic U (2010) Comparison of 980 nm laser and
bare-tip fibre with 1470 nm laser and radial fibre in the treatment
of great saphenous vein varicosities: a prospective randomized
clinical trial. Eur J Vasc Endovasc Surg 40:254–259
25. Roig JV, Garcia-Armengol J, Jordan JC, Moro D, Garcia-Granero
E, Alonso R (2010) Fistulectomy and sphincteric reconstruction
for complex cryptoglandular fistulas. Colorectal Dis 12:145–152
26. Go¨ttgensKW,SmeetsRR, StassenLP,BeetsG,BreukinkSO (2015)
Systematic review and meta-analysis of surgical interventions for
high cryptoglandular perianal fistula. Int J Colorect Dis 30:583–593
Tech Coloproctol
123
